The aim of this clinical trial is to learn if there is a correlation between the erythrocyte transfusion in the early neonatal period in premature infants and early and late complications of prematurity. The main questions it aims to answer are: * Do premature infants who receive blood transfusions within their first month of life have a higher risk of early prematurity complications, such as retinopathy of prematurity, necrotising enterocolitis, bronchopulmonary dysplasia, and intraventricular haemorrhage? * Do premature infants who receive blood transfusions during their first month of life have worse neurological and neurodevelopmental outcomes than those who do not? The first part of the study is retrospective, using data collected from participants' histories. The second part is prospective, evaluating neurological and neurodevelopmental outcomes at the age of six years.
Age range
6 Years – 7 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Motor function at the age of 6 years in premature infants who received erythrocyte transfusion compared to those who did not
Timeframe: From enrollment to the end of the neurologic assessment at 4 weeks.
Hearing assessment at the age of 6 years in premature infants who received erythrocyte transfusion compared to those who did not
Timeframe: From enrollment to the end of the hearing assessment at 4 weeks.
Visual assessment at the age of 6 years in premature infants who received erythrocyte transfusion compared to those who did not
Timeframe: From enrollment to the end of the hearing assessment at 4 weeks.
Neurodevelopmental outcome of premature infants who received erythrocyte transfusion compared to those who did not
Timeframe: From enrollment to the end of the neurologic assessment at 4 weeks.